March Marc	Note: State, local, tribal, and territorial (SLTT) partr	the fed	eral data collection. These fields have been moved to a				
March Marc	reporting for all partners. The following fields will be required weekly beginn	ing 12/	15/2021:	ent or t	tne rederai reporting requirements. Facilities are enco	uraged t	o work with relevant (SLIT) partners to ensure complete
Selection of the content of the cont	40d. Sotrovimab (Therapeutic D) Courses use The following fields will be required daily beginnin 3c. All pediatric inpatient beds 4c. Pediatric inpatient bed occupancy 5c. Pediatric ICU beds	ed in the	e last week	• 34.	. Previous day's admissions with laboratory-confirmed	d influenz	za virus infection
	 12c. Hospitalized ICU laboratory-confirmed C 						
March Marc		6	4a. All hospital inpatient bed occupancy	0	5a. ICU beds	0	6a. ICU bed occupancy
Table 1	o. Adult hospital inpatient beds	6	4b. Adult hospital inpatient bed occupancy	6	5b. Adult ICU beds	6	6b. Adult ICU bed occupancy
March Marc		^		^		^	
Marches Marc	•	6	10a. Total hospitalized pediatric suspected or laboratory-	6			12a. Total ICU adult suspected or laboratory-confirmed
	3 .	6	0 10b. Hospitalized pediatric laboratory-confirmed COVID-19 patients	6		^	0 A 12b. Hospitalized ICU adult laboratory-confirmed COVID-19 patients
Transfer September	3	~	U	~			12c. Hospitalized ICU pediatric laboratory-confirmed COVID- 19 patients (Optional)
March Marc		^					
	mergency Department						
		^		^			
March Marc	•	f to be co	onsidered compliant.				
March Marc	aboratory-confirmed COVID-19 and reakdown by age bracket:		suspected COVID-19 and breakdown by age bracket: 17b. Total adult	•	laboratory-confirmed COVID-19 breakdow age bracket: 18a. Total pediatric	0	18b. Total pediatric
	A value is required in this field for submission. 18-19		A value is required in this field for submission.	~	0-4 (Optional)	^	Unknown v
	20-29 Unknown		Unknown		Unknown	^	
March	40-49	^	40-49	^	Unknown	^	
	Unknown - 60-69		Unknown 60-69				
Table	70-79 Unknown -	^ `	70-79 Unknown	^ ~			
	Unknown	~	Unknown	~			
Marchen 19							
Section of the continue of the	asirivimab (REGN10933) / Imdevimab REGN10987) (Therapeutic A) a. Current inventory on hand (in courses)	0	Bamlanivimab and Etesevimab (Therapeutic	0	40c. Current Inventory on hand (in courses) (Optional)		
	9b. Courses used in the last week	•	40b. Courses used in the last week	6	40d. Courses used in the last week (Optional)	•	
March	itaff						
Part	Critical staffing shortage anticipated within a week (Y/N) pptional)	0					
	PE						
			30. Are you able maintain at least a three da	ay 🛈			
Company	>30 days 7c. Surgical and procedure masks		Yes 30e. Surgical and procedure masks	·			
	7d. Eye protection including face shields and goggles >30 days		30f. Eye protection including face shields and goggles Yes				
	>30 days 7f. Exam gloves (sterile and non-sterile)		Yes 30h. Exam gloves	•			
Westing the control of the control o	nfluenza						
Subtractions of the continue o	fluenza virus infection (Optional)	^	confirmed influenza virus infection) (Optional)	^	influenza virus infection (Optional)	^	
Company Comp	/accinations						
Security of the control of the contr	Previous week's COVID-19 vaccination doses administered healthcare personnel by your facility (Regardless of series)		42. Current healthcare personnel who have not yet received any COVID-19 vaccination doses (Optional)				
	5. Total number of current healthcare personnel (Optional)	•	96	~	110	^ ~	100
Manual and a control of the contro	5. Previous week's number of patients and other non- ealthcare personnel who received the first dose in a multi- ries of COVID-19 vaccination doses (Optional)	^	final dose in a series of COVID-19 vaccination doses or the single-dose vaccine by your facility (Optional)	^			
Stanford that Carpacing Stanford that Carpaci			ata collection. Hospitals no longer need to report these	data e	lements to the federal government.		
Medical Control of the Control of th	Note: State, local, tribal, and territorial (SLTT) partne.					aged to I	work with relevant (SLTT) partners to ensure complete
Modificación **Contraction of a contraction of a contrac							
Comment Comm	o. All adult hospital beds	•					
BDOverflow It desirates the properties of the p	/entilators						
Provides Day's COVID-19 Deaths The respect to the second of the second		^		^			
Provides Days COVID-19 Cestins Therapeutics Therapeutics	D/Overflow						
Therapoutics Thorapoutics Th	4. ED/overflow Unknown	^ ~					
Therapeutics Therapeutics Therefore		A					
Excellential to the control of the c							
Stacific Communication in the communication of the	emdesivir		•				
SCATE PPE The April 19 and 1	Unknown 2. Current inventory (Optional)	^ ~	Unknown 39d. Courses used in the last week (Optional) Unknown	6			
PPE St. PPE Supplies O 27. On hand supply (RURATION IN DATE): O 28. Are you able to obtain these returns the control of the			use without accompanying Etesevimab. The value in field 39d should be 0. Any doses of Bamlanivimab u with accompanying Etesevimab should be reported i	d for the sed			
PPE 25. PPE Capplies 4 2. On hand supply (NDMONDULA	itaff						
28. Are you able maintain at least a three day 1 and 10 percentage of the second and the second				•			
28. Are you able maintain at least a three day 1 and 10 percentage of the second and the second							
Working from managed portional discrete and discrete from the part of the facility for the first part of the facility for the first part of the facility for the first part of the facility for t							
Currown	re your PPE supply items managed (purchased, allocated, nd/or stored) at the facility level or, if you are part of a healt stem, at the health system level (or other multiple facility			0	UNITS/"EACHES") (Optional):	0	29. Are you able to obtain these items? 29a. Ventilator supplies (any supplies excluding medications)
28. Long and and promotive main's Chyldranial Chyldran	roup)?	•		•	Unknown 28b. Other respirators such as PAPRs or elastomerics (Opt	ional)	29b. Ventilator medications
28. Spelp-use gavers (Optional) Uniform 28. Spelp-use gavers (Optional) Uniform 28. Exp presection industry this shell uniform 29. Exp you able to maintain a supply of lands Uniform 29. Exp you able to maintain a supply of lands Uniform 20. If firer air any intical loaves, such as supply, shifting, capering or other insects place option feet (Spinnes) Uniform 31. Recabibilished painters 31. Exp or seal phanged feedet Uniform 32. Exp or seal phanged feedet Uniform 33. Exp or seal phanged feedet Uniform 34. Exp or seal phanged feedet Uniform 35. Exp or seal phanged feedet Uniform 36. Exp or seal phanged feedet Uniform 37. Exp or seal phanged feedet Uniform 38. Exp or seal phanged feedet Uniform 39. Exp or seal phanged feedet Uniform 30. Liberatory resal phanged feedet Uniform 30. Exp or seal phanged feedet Uniform 31. Exp or seal phanged feedet Uniform 32. Exp or seal phanged feedet Uniform 33. Exp or seal phanged feedet Uniform 34. Provious day's deaths for patients co-infected with both 0 (20) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4					Unknown 28d. Eye protection including face shields and goggles (Op	tional)	Unknown ▼ 29d. Other respirators such as PAPRs or elastomerics
Dichoom Cylindroom Cylind					Unknown 28e. Single-use gowns (Optional) Unknown	^	29e. Surgical and procedure masks Unknown ▼
30. Are you able maintain at least a three day supplies excluding medication Unknown 23°. Are you able to maintain a supply of bunde Unknown 20°. Are you able to maintain a supply of bunde Unknown 20°. Are you able to maintain a supply of bunde Unknown 20°. Are you able to maintain a supply of bunde Unknown 20°. If some or any priced issue, such as supply, staffing, and or any critical issue, such as supply, staffing, and any critical issue, such as supply, s					Unknown 28g. Exam gloves (single) (Optional)	~	29g. Single-use gowns
30. Are you able maintain at least a three day supplies (any supplies excluding medications) Unknown 31. Does your facility re-use or extend the use of PPE7 (Optional) 31. Reusatile/stunderable isolation gowns Unknown 31. Reusatile/stunderable isolation gowns Unknown 31. PAPRs or elastomerics Unknown 31. NPS respirators Unknown 32. Laboratory - nearl phanyngeal swabs Unknown 33. Laboratory - viral transport media Unknown 34. Saboratory - viral transport media Unknown 35. Saboratory - viral transport media Unknown 36. Total hospitalized patients to infected with BOTH 37. Previous day's influenza deaths, luboratory confirmed of the province of COVID-19 AND laboratory confirmed of the near warrs infection (Optional)							29h. Exam gloves Unknown ▼ 29i. Are you able to maintain a supply of launderable gowns?
30a. Ventilator supplies (any supplies excluding medications) Unknown 31a. Reusablerlaunderable isolation gowns Unknown 31b. PAPRs or elastomerics Unknown 31c. N95 respirators Unknown 42c. N95 Respirators Unknown 43c. N95 Respirators Unknown		y ®		0	32 If there are a recommendation of the second of the seco		
Unknown Influenza 31c. N95 respirators Influenza 31c. N95 respirators Unknown Influenza 31c. N95 respirators Unknown Influenza 31c. N95 respirators Influenza 31c. N95 respirator 31c. N95 respira	Unknown		Unknown	•	capacity, or other issues about which you would like to receive direct contact, please explain here. (Optional)	6	
Unknown Olicity - nasal swabs Unknown Olicity - viral transport media Unknown Olicity - viral transport media Unknown Olicity - viral transport media Olicity	Unknown Od. Other respirators such as PAPRs or elastomerics	_	Unknown 31c. N95 respirators				
Influenza 36. Total hospitalized patients co-infected with BOTH laboratory-confirmed cOVID-19 AND laboratory-confirmed influenza virus infection (Optional) 37. Previous day's influenza deaths (laboratory-confirmed influenza virus infection) (Optional) 48. Previous day's deaths for patients co-infected with both cOVID-19 AND laboratory-confirmed influenza virus infection (Optional) 49. Optional optiona	Unknown Dj. Laboratory - nasal swabs						
36. Total hospitalized patients co-infected with BOTH laboratory-confirmed COVID-19 AND laboratory-confirmed influenza virus infection (Optional) 37. Previous day's influenza deaths (laboratory-confirmed influenza virus infection) (Optional) 38. Previous day's deaths for patients co-infected with both COVID-19 AND laboratory-confirmed influenza virus (Optional) (Optional)	Ok. Laboratory - viral transport media	•					
laboratory-confirmed COVID-19 AND laboratory-confirmed 37. Previous day's influenza deaths (laboratory-confirmed influenza virus infection (Optional) influenza virus infection) (Optional) (Optional)	nfluenza						
	boratory-confirmed COVID-19 AND laboratory-confirmed fluenza virus infection (Optional)	^	influenza virus infection) (Optional)	^	COVID-19 AND laboratory-confirmed influenza virus (Optional)	^	

U.S. HEALTHCARE COVID-19 PORTAL OMB No. 0990-0478 Expires: 08/31/2024

Welcome, Scott Jubeck ▼ POWERED BY TélleTracking